United Therapeutics Corporation

American biotechnology company founded in 1996, known for pulmonary hypertension treatments and organ transplant technologies, headquartered in Silver Spring, Maryland.

United Therapeutics was founded in 1996 by Martine Rothblatt after her daughter was diagnosed with pulmonary arterial hypertension, a rare and life-threatening condition. Rothblatt, a lawyer and entrepreneur, founded the company to develop treatments for pulmonary hypertension and other rare diseases. The company initially focused on developing prostacyclin analogs for pulmonary hypertension treatment.

The company developed Remodulin, a prostacyclin analog for pulmonary arterial hypertension, which received FDA approval in 2002. Remodulin became United Therapeutics' first commercial product and established the company as a leader in pulmonary hypertension treatment. The company continued to develop other treatments including Tyvaso, an inhaled prostacyclin approved in 2009.

In the 2010s, United Therapeutics expanded its portfolio beyond pulmonary hypertension. The company developed Orenitram, an oral prostacyclin approved in 2013. United Therapeutics also invested in organ transplant technologies, developing lung preservation systems to increase the supply of transplantable organs. The company acquired companies with complementary technologies to expand its organ transplant portfolio.

Recent strategic direction has focused on innovative organ transplant technologies and rare disease treatments. United Therapeutics has invested in lung preservation systems and xenotransplantation research to address organ shortage. The company has also continued to develop new treatments for pulmonary hypertension and other rare diseases.